RxDoctor Payments DataLook up a doctor →

Jessica Glassman, NP

Family · Mishawaka, INNPI 1992054183

Payments from drug & device makers

$43,136in general payments, 2019–2025

Across 685 payments — averaging $62.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$12K
  • Biohaven Pharmaceutical Holding Company Ltd.$11K
  • Axsome Therapeutics, Inc.$4K
  • Pfizer$3K
  • AbbVie$1K
  • Bristol Myers Squibb$969
  • plus $10K from 50 others

What the payments were for

  • Consulting fees$1,3503%
  • Speaking & faculty fees$25,96460%
  • Travel & lodging$8632%
  • Food & beverage$14,77334%
  • Education$1860%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biohaven Pharmaceuticals, Inc.30$11,936
Biohaven Pharmaceutical Holding Company Ltd.18$11,144
Axsome Therapeutics, Inc.9$4,030
Pfizer24$3,467
AbbVie(2 entities)49$1,158
Bristol Myers Squibb45$969
Biogen41$805
Amgen(2 entities)28$726
Teva Pharmaceuticals USA, Inc.48$606
AstraZeneca(2 entities)27$520
Novartis25$489
UCB, Inc.29$484
Vanda Pharmaceuticals Inc.12$457
Neurocrine Biosciences, Inc.17$340
Eisai Inc.10$336
Argenx US, Inc.14$333
Jazz Pharmaceuticals Inc.10$305
Lundbeck LLC13$304
EMD Serono, Inc.17$302
Johnson & Johnson(2 entities)12$287
Genentech USA, Inc.16$286
Catalyst Pharmaceuticals, Inc.8$279
SK Life Science, Inc.11$271
Amneal Pharmaceuticals LLC13$261
Livanova USA, Inc.18$250
Neurelis, Inc.11$244
Banner Life Sciences, LLC10$244
Lilly USA, LLC14$204
TG Therapeutics, Inc.9$201
Mallinckrodt Hospital Products Inc.8$184
Sanofi8$162
Takeda Pharmaceuticals U.S.A., Inc.7$159
MDD US Operations, LLC8$157
Otsuka America Pharmaceutical, Inc.8$152
Acorda Therapeutics, Inc8$131
Acadia Pharmaceuticals Inc6$102
Cala Health, Inc.5$94
Ipsen Biopharmaceuticals, Inc4$82
Grifols USA, LLC4$78
Abbott4$64
E.r. Squibb & Sons, L.L.C.3$58
Springworks Therapeutics, Inc.2$48
CSL Behring3$47
Supernus Pharmaceuticals, Inc.2$44
Tanabe Pharma America, Inc.2$42
Cycle Pharmaceuticals Inc2$42
Scilex Pharmaceuticals Inc.2$37
Adamas Pharmaceuticals, Inc.2$31
Avanir Pharmaceuticals, Inc.2$29
Kyowa Kirin, Inc.1$28
Tersera Therapeutics LLC1$27
Octapharma USA, Inc.1$23
Impel Pharmaceuticals Inc.1$23
Amylyx Pharmaceuticals, Inc.1$22
Sanofi-aventis U.S. LLC1$18
Upsher-smith Laboratories LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,136 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$55,097
Medicare patients
289
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate288$470,798
VumerityDiroximel Fumarate28$261,069
BetaseronInterferon Beta-1b17$192,450
TecfideraDimethyl Fumarate20$187,061
CopaxoneGlatiramer Acetate23$175,144
RebifInterferon Beta-1a/Albumin13$169,992
Emgality PenGalcanezumab-Gnlm199$159,187
QuliptaAtogepant92$147,304
UbrelvyUbrogepant132$142,274
AustedoDeutetrabenazine16$135,839
Aimovig AutoinjectorErenumab-Aooe123$117,209
Ajovy AutoinjectorFremanezumab-Vfrm59$63,725
AptiomEslicarbazepine Acetate22$53,822
FycompaPerampanel36$48,806
VimpatLacosamide22$44,245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Zavzpret, Dilantin$3,467$500,525348 claims
BiogenVumerity, Tecfidera$805$448,12948 claims
Teva Pharmaceuticals USA, Inc.Copaxone, Austedo$606$310,98239 claims
AbbVieQulipta, Ubrelvy$1,158$289,577224 claims
EMD Serono, Inc.Rebif$302$169,99213 claims
UCB, Inc.Vimpat, Briviact, Nayzilam$484$80,98253 claims
Eisai Inc.Fycompa$336$48,80636 claims
Amneal Pharmaceuticals LLCRytary$261$32,11920 claims
Avanir Pharmaceuticals, Inc.Nuedexta$29$26,69717 claims
SK Life Science, Inc.Xcopri$271$18,16118 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$44$16,47412 claims
Lilly USA, LLCReyvow$204$11,95016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Mishawaka

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →